Skip to content

Rebuilding the Intestine. Restoring Lives.

Pioneering regenerative therapy for Short Bowel Syndrome (SBS) with the first device designed to stimulate new intestinal growth.

*The Eclipse XL1 is currently under development and not available for clinical use.

Introducing the Eclipse XL1.

The Eclipse XL1 is the first device designed to regenerate healthy intestinal tissue using your body’s own biology. Our approach may offer patients a chance to grow their intestine, without transplant or dependence on parenteral nutrition.

Why Short Bowel Syndrome Needs a New Solution.

SBS patients face a lifetime of complications—malnutrition, constant medical care, and limited quality of life. Current treatments are limited and invasive, often requiring long-term parenteral nutrition or transplant. We’re building a future where regeneration, not replacement, is the path forward.

Total Parenteral Nutrition (TPN)

  • Lifelong Intravenous (IV) feeding and nutritional support
  • Frequent hospitalizations for venous catheter-associated complications (infections, displacement, etc.)
  • Toxicity often leading to end-stage liver disease

Drug Therapy (Teduglutide Injections)

  • Daily injections
  • Minimal improvement in absorption (max 20%)
  • TPN/IV nutrition still required

Surgery and Intestinal Transplantation

  • May not increase nutrient absorption
  • May require lifelong immunosuppression drugs
  • High risk of infection, rejection, death

Driven by Science. United by Purpose.

We’re a team of physicians, engineers, and entrepreneurs committed to changing the future of gastrointestinal care. Our mission: harness the body’s healing potential to restore what was lost.

Proudly Partnered

Our commitment to patient-centered innovation is driven by our partnerships with some of the leading healthcare organizations in the world. Eclipse Regenesis is proudly partnered with Boston Children’s Hospital, Cincinnati Children’s, UCLA Health, and Stanford Medicine. Together with our partners, we continue to pioneer the next generation of treatment for patients with Short Bowel Syndrome (SBS).

Ready to Join Us In Redefining Intestinal Healing?